Cassiopea Hails Breezula's 'Good Hair Day' And Plans FDA Talks On Phase III

16 Apr 2019

• By Sten Stovall

Italy-based Cassiopea says “very positive results” from Breezula's 12-month Phase II alopecia trial support progressing it to Phase III, particularly given the clean safety profile.

BaldingMan — Cassiopea Will Now Talk With FDA About Phase III trialing in men • Source: Shutterstock

Cassiopea Hails Breezula's 'Good Hair Day' And Plans FDA Talks On Phase III

More from Clinical Trials

More from R&D